Kymera Therapeutics
KYMR
126 hedge funds and large institutions have $1.93B invested in Kymera Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 60 increasing their positions, 32 reducing their positions, and 19 closing their positions.
312% more call options, than puts
Call options by funds: $10.6M | Put options by funds: $2.56M
88% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 32
3.77% more ownership
Funds ownership: 84.6% → 88.38% (+3.8%)
2% less funds holding
Funds holding: 128 → 126 (-2)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
30% less capital invested
Capital invested by funds: $2.76B → $1.93B (-$826M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$27.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$25.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$19.1M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$17.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$42.5M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$18.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.9M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$12.7M |
| 5 |
Jennison Associates
New York
|
-$11.6M |
KYMR Hedge Fund Activity: Q1 2022 in Review
126 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q1 2022, worth a combined $1.93B — down 30% from $2.76B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KYMR and 17 opened new positions — a net loss of 2 holders — while 32 trimmed existing stakes and 60 added.
The largest buyer was Pictet Asset Management (Switzerland), opening a new position worth an estimated $27.3M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $42.5M sold.
- 126 institutional investors held Kymera Therapeutics (KYMR) as of Q1 2022, down from 128 in Q4 2021.
- Funds reported $1.93B of Kymera Therapeutics stock for Q1 2022, down 30% quarter-over-quarter.
- 17 funds opened new Kymera Therapeutics positions in Q1 2022 and 19 closed out, a net change of -2 holders.
- The largest Kymera Therapeutics buyer in Q1 2022 was Pictet Asset Management (Switzerland), an estimated $27.3M added.
- The largest Kymera Therapeutics seller in Q1 2022 was Avidity Partners Management, an estimated $42.5M sold.
Based on aggregated 13F filings for Q1 2022.